Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.